ATR
Premium GrowerAI neutralAptarGroup, Inc. · Healthcare · United States · $8.0B cap · $76.2M/day traded
$143.08 -0.7% · close 11 Nov · scored 12 Nov
Premium Grower: Strong business with the market behind it, priced at a premium.
Around its 29 Oct results, analysts left next year's EPS estimate little changed.
As of 12 Nov 2026, the MoatMap Score for AptarGroup, Inc. (ATR) is 65/100, ranked against 25,000+ stocks in 38 markets (Quality 60, Value 44, Momentum 57, each scored against its sector).
Does the score work? Each tenth of the ranking, tracked monthly. See the record →
AptarGroup makes nasal sprays, inhaler and injectable components, and consumer dispensing pumps. Its pharma unit is a high-margin franchise protected by regulatory approvals that lock its devices into drug filings, and it reported record second-quarter sales. The beauty and food packaging businesses are lower quality and more exposed to consumer spending, and nothing here points to a mispricing large enough to stand out.
ABOUT APTARGROUP, INC.
Read
AptarGroup designs and manufactures innovative dispensing, sealing, and active packaging solutions for beauty, personal care, pharma, and food & beverage markets. It benefits from extensive intellectual property, advanced manufacturing capabilities, and long-standing relationships with leading global brands. The company is a global leader in value-added dispensing and active packaging, serving critical functions from product preservation to precise drug delivery.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.3B | 3.5B | 3.6B | 3.8B | 4.4% | 4.0B | 4.0B | 4.1B | 4.7% |
| EPS | 3.66 | 4.34 | 5.65 | 5.97 | 17.7% | 4.14 | 5.78 | 6.45 | 3.9% |
| Shares | 65.2M | 65.9M | 66.5M | 64.2M | -1.5% | 63.4M | — | — | — |
| Debt | 1.2B | 1.2B | 1.1B | 1.5B | 7.9% | 1.4B | — | — | — |
| Equity | 2.1B | 2.3B | 2.5B | 2.7B | 9.1% | — | — | — | — |
| Op CF | 478.6M | 575.2M | 643.4M | 570.0M | 6.0% | 573.5M | — | — | — |
| Inv CF | -295.6M | -324.5M | -396.7M | -331.4M | — | — | — | — | — |
| Fin CF | -162.1M | -171.6M | -225.3M | -77.5M | — | — | — | — | — |
No clear trend: not near its 52-week low, and not in a steady uptrend.
Calmer than 83% of stocks we rank over the past year (volatility 25% a year).
How this is worked out
The MoatMap Score weighs the business, its price and its trend. The price check reads only the chart: the price side of the Momentum score, in words.
The rules: Still falling is a new 52-week low in the last two weeks, at least 25% below the high. Finding a floor is no new low since. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average and within 15% of the high.
In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn (the Turning up rule above) cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.
What it measures: how much the price moved day to day over the past year, scaled to a yearly figure (annualised volatility) and ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ATR are excluded.
| Ticker | Company | Mkt Cap | Score |
|---|---|---|---|
| ATR | AptarGroup, Inc.(you) | $8.0B | 65 |
| TFX | Teleflex Incorporated | $5.8B | 65 |
| COO | The Cooper Companies, Inc. | $11.6B | 68 |
| SOLV | Solventum Corporation | $14.5B | 66 |
| MMED | MiniMed Group, Inc. | $5.2B | 60 |
| AVTR | Avantor, Inc. | $11.7B | 74 |
| BAX | Baxter International Inc. | $13.1B | 74 |
| RGEN | Repligen Corporation | $11.2B | 53 |
| ICUI | ICU Medical, Inc. | $4.2B | 72 |
| ATRC | AtriCure, Inc. | $3.0B | 61 |
Peer medians: ROE -31.0% · P/E 25.7x · Gross margin 63.3%
Company Deep Dive
A 10,000-word report: the business and its segments, what management promised on earnings calls and whether it delivered, the competition, and how things could turn out.